Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.

MLA

Laffin, Luke J., et al. “Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.” JAMA: Journal of the American Medical Association, vol. 330, no. 12, Sept. 2023, pp. 1140–50. EBSCOhost, https://doi.org/10.1001/jama.2023.16029.

APA

Laffin, L. J., Rodman, D., Luther, J. M., Vaidya, A., Weir, M. R., Rajicic, N., Slingsby, B. T., & Nissen, S. E. (2023). Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA: Journal of the American Medical Association, 330(12), 1140–1150. https://doi.org/10.1001/jama.2023.16029

Chicago

Laffin, Luke J., David Rodman, James M. Luther, Anand Vaidya, Matthew R. Weir, Natasa Rajicic, B. T. Slingsby, and Steven E. Nissen. 2023. “Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.” JAMA: Journal of the American Medical Association 330 (12): 1140–50. doi:10.1001/jama.2023.16029.